Arcutis Biotherapeutics announced new Phase III clinical trial data for Zoryve cream 0.05%, showing rapid itch relief and skin clearance in infants aged three to 24 months with atopic dermatitis, targeting a US Food and Drug Administration decision by February 2027.
Atopic dermatitis affects 60% of pediatric patients within their first year of life, causing severe pruritus that disrupts sleep and creates emotional distress for caregivers.
Roflumilast Cream Reduces Itching in Infants with Atopic Dermatitis
At the annual meeting of the American Academy of Allergy, Asthma & Immunology in Phoenix, Arcutis presented findings from the INTEGUMENT-INFANT trial involving 101 infants with mild-to-moderate atopic dermatitis, as irpharm.com reported.
Caregiver reports indicated that 46.6% of infants experienced a 25% or greater reduction in itching just 10 minutes after the first application of roflumilast cream 0.05%. That proportion rose to 66.7% four hours post-application, while the treatment success rate on the Worsting Itching Numeric Scale reached 72.7% by the final evaluation.
“Infant atopic dermatitis is a lifelong chronic condition compounded by the immature skin barrier and immune system of the young patient, making management exceptionally challenging,”
said Mark Boguniewicz, professor of pediatrics at National Jewish Health and the University of Colorado School of Medicine.
Global skin symptoms shifted from moderate to mild severity within four weeks of treatment. Scores on the Patient-Oriented Eczema Measure dropped from a baseline average of 14.5 to 7.9 at week two and 6.5 at week four.
| Evaluation Timeline | Itch Reduction (>=25%) | POEM Severity Score |
|---|---|---|
| Baseline | N/A | 14.5 (Moderate) |
| Week 2 | Not Reported | 7.9 |
| Week 4 | Not Reported | 6.5 (Mild) |
Safety and Regulatory Timeline for 2027
Among the 101 infants in the trial, zero serious adverse events or severe treatment-emergent adverse events were recorded. Application-site reactions such as stinging or erythema were absent in at least 97.9% of infants across all evaluation timepoints.
Arcutis is pursuing a supplemental new drug application to lower the indication age to three months.
“This caregiver-reported data reaffirms the potential of Zoryve as a well-tolerated, non-steroidal option to manage the distressing symptoms of atopic dermatitis that begin in infancy,”
said Patrick Burnett, chief medical officer at Arcutis.
The FDA has set a Prescription Drug User Fee Act target action date of February 23, 2027, for the supplemental application.
References
- American Academy of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Proceedings, Phoenix, AZ.
- INTEGUMENT-INFANT Clinical Trial Data Presentation, Arcutis Biotherapeutics.
- US Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) Tracking Data.
